Wholesale Peptide: FDA Warning Letter Record (June 17, 2026)

Updated August 28, 2026

FDA issued warning letter 729447 to Wholesale Peptide of Brooksville, Florida on June 17, 2026, following a May 2026 review of the firm's website. Two products were cited: "Prostamax" and "Gonadorelin" — neither of them GLP-1-class. This entry is recorded separately from the 2024 and 2026 batches because of what the letter cites as evidence: alongside conventional therapeutic claims, the agency quoted product-page language written entirely in the research register, describing findings in experimental subjects and laboratory settings, and treated that language as evidence the products were intended as drugs for human use.

Record at a glance

Field	Entry
Recipient	Wholesale Peptide, 7394 Broad Street, Brooksville, FL 34601
Action	FDA warning letter, reference number 729447 (MARCS-CMS 729447)
Date issued	June 17, 2026 (posted June 23, 2026)
Website reviewed	May 2026 — roughly a six-week interval between review and letter
Issuing office	Center for Drug Evaluation and Research, Office of Compliance, Office of Unapproved Drugs and Labeling Compliance
Signed	Tina Smith, M.S., Captain, U.S. Public Health Service, Director
Products cited	"Prostamax" and "Gonadorelin"
Statutes cited	FD&C Act §§ 201(g)(1), 201(p), 301(d), 505(a); 21 U.S.C. 321(g)(1), 321(p), 331(d), 355(a); intended use per 21 CFR 201.128
Response window	Written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days
Outcome	No close-out letter located as of this entry's date

What this letter changes about scope

The research-peptide warning letters most often discussed date from December 10, 2024 and March 31, 2026, and concerned GLP-1-class compounds. This letter does not. "Prostamax" and "Gonadorelin" sit outside the GLP-1 category entirely, and the letter issued from the same office, under the same statutory theory, in mid-2026. For anyone tracking where enforcement attention falls, the observable pattern is that the compound class is not the boundary. The letters continue, the office is the same, and the products cited are whatever the reviewed website was selling.

The Prostamax citations — the conventional case

For "Prostamax," the agency quoted product-page statements that assert disease effects directly. FDA reproduced, among others, the claims that the product reduces chronic inflammation in the prostate, swelling and vascular hyperemia and the page heading Prostamax for Enlarged Prostate, together with statements referencing benign prostatic hyperplasia and prostatitis by name. Language of that kind — a named condition plus an asserted effect on it — is the long-established basis for an intended-use finding, and it appears in most letters in this index. Nothing about that half of the letter is novel.

The Gonadorelin citations — why this record exists

The second half is different, and it is the reason this page is in the index. For "Gonadorelin," FDA quoted the following from the firm's product page, in full:

Spermatogenesis Research: Investigations show how gonadorelin affects testosterone production and supports testes function in experimental subjects.

Emerging research is investigating gonadorelin's applications in cancer research, particularly in hormone-dependent cancers. While this research is in early stages, scientists have explored: Prostate Cancer Models: Studies on prostate cancer cell growth and progression in laboratory settings.

Read those against the Prostamax quotations above. They name no condition the reader is invited to treat. They promise nothing. They are not addressed to the reader at all — there is no second person anywhere in them. They attribute findings to investigations and scientists, they place those findings explicitly in experimental subjects and laboratory settings, and one of them volunteers that the research is in early stages. That is the register of a laboratory catalog describing what has been studied.

The agency cited it as evidence of intended use as a human drug.

Where the research-use-only disclaimer ended up

The firm's labeling carried both a RESEARCH USE ONLY statement and a not for human consumption statement. The letter addresses them in a single sentence, and that sentence is not in the body of the letter — it is footnote 1: Despite statements on your product labeling marketing your products for, "RESEARCH USE ONLY" and "not for human consumption," evidence obtained from your product labeling, including your website establishes that your products are intended to be drugs for human use.

The placement is itself a small piece of the record. In earlier letters the disclaimer was taken up in the body of the analysis. Here it is disposed of in a footnote, in one sentence, without argument. That is how an agency handles a point it considers settled.

Two other things the letter says plainly

The letter states a public-health rationale specific to the delivery route: injectable drug products can pose risks of serious harm to users, because such products bypass some of the body's key defenses against toxins and microorganisms. The reasoning is about the route, not the molecule.

Its closing warning is also sharper than the phrasing used in the 2024 batch. The letter states that failure to adequately address the violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. The words without further notice do not appear in that construction in every earlier letter in this index.

How to read this record

A warning letter is an agency compliance action stating the agency's position. It is not a court judgment, and no finding here has been adjudicated. Outcomes are not always published alongside the letter, and no close-out letter for reference number 729447 was located when this entry was compiled.

What the letter establishes for the record is narrower and more useful than a verdict: it shows what the agency read, on what date, and what it concluded from it. For a buyer evaluating any vendor's product pages, the practical consequence is that the presence of careful research framing on a page does not, on this record, tell you the page has been written outside the agency's stated theory of intended use. The 2024–2026 sequence in this index — from benefit-framed claims, through citation-formatted reporting, to the language quoted above — is a record of that theory being applied to progressively more cautious writing, and it is available for anyone to read in the primary documents linked below.

Sources

US FDA — Warning Letter, Wholesale Peptide, reference number 729447, June 17, 2026. fda.gov/…/wholesale-peptide-729447-06172026 — all quotations on this page are taken from this document.
US FDA — Warning Letters index (searchable). fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
US FDA — FDA Roundup, December 17, 2024 (agency summary of the December 10, 2024 batch, for comparison). fda.gov